A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols)

Multiple Sclerosis Journal

Volumn 18, Issue 2, 2012, Pages 219-228

  Notcutt, W ^a   Langford, R ^b   Davies, P ^c   Ratcliffe, S ^d   Potts, R ^e  

^a JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d MAC UK Neuroscience Ltd   (United Kingdom)

^e Porton Down Science Park   (United Kingdom)

Author keywords

cannabidiol; cannabinoids; delta 9 tetrahydrocannabinol; endocannabinoid system; multiple sclerosis; nabiximols; Sativex; spasticity

Indexed keywords

NABIXIMOLS; PLACEBO;

ADULT; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCULOSKELETAL STIFFNESS; PAIN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPASTICITY; TREATMENT DURATION; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; URINARY TRACT INFECTION;

EID: 84856757851     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511419700     Document Type: Article

References (30)

1. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 ; 10: 589-595 (Pubitemid 39207235)
2. Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations of multiple sclerosis prevalence in French farmers. J Neurol Neurosurg Psychiatry. 2007 ; 78: 707-709 (Pubitemid 46998840)
3. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005 ; 252 (Suppl 5). v3 - v9
4. Kesselring J, Beer S. Rehabilitation in multiple sclerosis. Adv Clin Neurosci Rehabil. 2002 ; 2: 6-8
5. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis (Cochrane Review). The Cochrane Library. 2001 ; ( Issue 3 ):
6. Smith CR, La Rocca NG, Giesser BS, Scheinberg LC. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology. 1991 ; 41: 1829-1831
7. Beard S, Hunn A, et al. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003 ; 7: 1-111
8. Young RR. Spasticity: a review. Neurology. 1994 ; 44: 512-520
9. Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005 ; 27: 2-6 (Pubitemid 40124834)
10. Wood DE, Burridge JH, van Wijck FM, et al. Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature. Disabil Rehabil. 2005 ; 27: 19-32 (Pubitemid 40124836)
11. Lance J Spasticity disordered motor control. Feldman RJ Young RR Koella WP, ed. Chicago: Year Book ; 1980: 485-494.
12. House of Lords Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. Session 1997-98, 9th report.
13. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000 ; 404: 84-87 (Pubitemid 30143137)
14. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997 ; 74: 129-180 (Pubitemid 27337346)
15. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol. 2000 ; 5: 37-46 (Pubitemid 30085432)
16. Zuardi AW, Shirakawa L, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology. 1982 ; 76: 245-250 (Pubitemid 12129400)
17. Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomised, placebo controlled study on 160 patients. Mult Scler. 2004 ; 10: 434-441 (Pubitemid 39117341)
18. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007 ; 14: 290-296 (Pubitemid 46384865)
19. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex, on spasticity in people with multiple sclerosis. Mul Scler. 2010 ; 16: 707-714
20. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post-hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther. 2008 ; 30: 974-985 (Pubitemid 351799873)
21. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation. 2009 ; 24: 333-340
22. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006 ; 12: 639-645 (Pubitemid 46940638)
23. Russell LJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000 ; 6: 250-257
24. US Food and Drug Administration. Choice of Control Group and Related Issues in Clinical Trials-Guidance for Industry. 2001. www.fda.gov/ RegulatoryInformation/Guidances/ucm125802.htm.
25. Temple R. Government viewpoint of clinical trials. Drug Inf J. 1982 ; 1: 10-17
26. Serpell MG, Sarantis N. Long-term open-label treatment with Sativex#174;, a cannabis-based medicine, in neuropathic pain of various aetiologies, and spasticity due to multiple sclerosis. Eur J Neurol. 2006 ; 13: 239
27. Bingel U, Wanigasekera V, Wiech K, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011 ; 3: 70ra14
28. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006 ; 19: 233-238 (Pubitemid 44309479)
29. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010 ; 32: 451-459
30. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex#174;), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011 2011 ;: